Synapse

← Cancer Research Communications

Papers in Cancer Research Communications

Page 10 · newest first

  1. SREBP-dependent regulation of lipid homeostasis is required for progression and growth of pancreatic ductal adenocarcinomaCancer Research Communications · 2024
  2. MYC is sufficient to generate mid-life high-grade serous ovarian and uterine serous carcinomas in a p53-R270H mouse modelCancer Research Communications · 2024
  3. A drug discovery pipeline for MAPK/ERK pathway inhibitors in C. elegansCancer Research Communications · 2024
  4. Systematic Evaluation of Tyrosine Kinase Inhibitors as OATP1B1 Substrates Using a Competitive Counterflow ScreenCancer Research Communications · 2024
  5. A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle Invasive Bladder CancerCancer Research Communications · 2024
  6. Engineering oncogenic hotspot mutations on SF3B1 via CRISPR-directed PRECIS mutagenesisCancer Research Communications · 2024
  7. Activation of Cell Intrinsic Signaling in CAR-T cells via a Chimeric IL7R DomainCancer Research Communications · 2024
  8. Targeting TREX1 induces innate immune response in drug-resistant Small Cell Lung CancerCancer Research Communications · 2024
  9. Long-lasting response to lorlatinib in patients with ALK-driven relapsed or refractory neuroblastoma monitored with circulating tumor DNA analysisCancer Research Communications · 2024
  10. ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid TumorsCancer Research Communications · 2024
  11. Health disparities among cancer patients who received molecular testing for biomarker-directed therapyCancer Research Communications · 2024
  12. The Proteogenomics of Prostate Cancer RadioresistanceCancer Research Communications · 2024
  13. Netrin-1 and UNC5B Cooperate with Integrins to Mediate YAP-Driven CytostasisCancer Research Communications · 2024
  14. A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma (ACC) Cell Lines, PDX, and Patient SamplesCancer Research Communications · 2024
  15. Phase 1 study of simlukafusp alfa (FAP-IL2v) with or without atezolizumab in Japanese patients with advanced solid tumorsCancer Research Communications · 2024
  16. MYBL2 Drives Prostate Cancer Plasticity: Inhibiting its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate CancerCancer Research Communications · 2024
  17. Poor prognosis among radiation associated bladder cancer is defined by clinicogenomic featuresCancer Research Communications · 2024
  18. Inferring characteristics of the tumor-immune microenvironment of HNSCC patients from single-cell transcriptomics of peripheral bloodCancer Research Communications · 2024
  19. ANGPTL4 suppresses clear cell renal cell carcinoma via inhibition of lysosomal acid lipaseCancer Research Communications · 2024
  20. Loss of STK11 Suppresses Lipid Metabolism and Attenuates KRAS-Induced Immunogenicity in Patients with Non-Small Cell Lung CancerCancer Research Communications · 2024
  21. Impact of Neoadjuvant Immunotherapy on Recurrence-Free Survival in Patients with High-Risk Localized HCCCancer Research Communications · 2024
  22. Mathematical Modeling of Tumor Growth in Preclinical Mouse Models with Applications in Biomarker Discovery and Drug Mechanism StudiesCancer Research Communications · 2024
  23. Coordinated targeting of S6K1/2 and AXL disrupts pyrimidine biosynthesis in PTEN-deficient glioblastomaCancer Research Communications · 2024
  24. Characterizing relationships between T-cell inflammation and outcomes in patients with high-risk neuroblastoma according to mesenchymal and adrenergic signaturesCancer Research Communications · 2024
  25. Mast cell infiltration and subtype promote malignant transformation of oral precancer and progression of oral cancerCancer Research Communications · 2024
  26. Role of Forkhead Box P3 in Interferon γ-mediated PD-L1 Expression and Bladder Cancer Epithelial-to-Mesenchymal TransitionCancer Research Communications · 2024
  27. Secondary endpoint utilization and publication rate among phase III oncology trialsCancer Research Communications · 2024
  28. High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase 2 TrialCancer Research Communications · 2024
  29. Yttrium-90 Induces an Effector Memory Response with Neoantigen Clonotype Expansion: Implications for ImmunotherapyCancer Research Communications · 2024
  30. Tumoral Interferon Beta Induces an Immune-Stimulatory Phenotype in Tumor-Associated Macrophages in Melanoma Brain MetastasesCancer Research Communications · 2024
  31. Development and Application of Genetic Ancestry Reconstruction Methods to Study Diversity of Patient-Derived Models in the NCI PDXNet ConsortiumCancer Research Communications · 2024
  32. Acetalax (Oxyphenisatin Acetate, NSC 59687) and Bisacodyl Cause Oncosis in Triple-Negative Breast Cancer Cell Lines by Poisoning the Ion Exchange Membrane Protein TRPM4Cancer Research Communications · 2024
  33. A first-in-human phase I clinical study with MVX-ONCO-1, a personalized active immunotherapy, in patients with advanced solid tumors.Cancer Research Communications · 2024
  34. Anti-HDGF antibody targets EGFR tyrosine kinase inhibitor-tolerant cells in NSCLC patient-derived xenograftsCancer Research Communications · 2024
  35. Clinical efficacy of the HIV protease-inhibitor Indinavir in combination with chemotherapy for advanced classic Kaposi’s sarcoma treatment: a single-arm, phase II trial in the elderlyCancer Research Communications · 2024
  36. BRCA status dictates Wnt responsiveness in epithelial ovarian cancerCancer Research Communications · 2024
  37. Synergistic effects of PARP inhibition and cholesterol biosynthesis pathway modulationCancer Research Communications · 2024
  38. Exploring Disparities in Pancreatic Adenocarcinoma Outcomes Among Asian and Pacific Islander SubgroupsCancer Research Communications · 2024
  39. The tumor microbiome as a predictor of outcomes in patients with metastatic melanoma treated with immune checkpoint inhibitorsCancer Research Communications · 2024
  40. Membrane-bound heat shock protein mHsp70 is required for migration and invasion of brain tumorsCancer Research Communications · 2024
  41. Exosomal Thomsen–Friedenreich Glycoantigen: A New Liquid Biopsy Biomarker for Lung and Breast Cancer DiagnosesCancer Research Communications · 2024
  42. Age-related increases in fibroblast-secreted IGFBP2 increase melanoma cell invasion and lipid synthesis.Cancer Research Communications · 2024
  43. Estrogen Receptor Blockade Potentiates Immunotherapy for Liver Metastases by Altering the Liver Immunosuppressive MicroenvironmentCancer Research Communications · 2024
  44. Tumor Vessel Normalization via PFKFB3 Inhibition Alleviates Hypoxia and Increases Tumor Necrosis in Rectal Cancer upon RadiotherapyCancer Research Communications · 2024
  45. FLT3/CD99 Bispecific antibody-based nanoparticles (BiAbs) for Acute Myeloid LeukemiaCancer Research Communications · 2024
  46. p300 KAT Regulates SOX10 Stability and Function in Human MelanomaCancer Research Communications · 2024
  47. Spatial landscape of malignant pleural and peritoneal mesothelioma tumor immune microenvironmentCancer Research Communications · 2024
  48. IFN-γ production by functionally reprogrammed Treg cells promotes anti-tumor efficacy of OX40/CD137 bispecific agonist therapyCancer Research Communications · 2024
  49. p53R172H and p53R245W Hotspot Mutations Drive Distinct Transcriptomes in Mouse Mammary Tumors Through a Convergent Transcriptional MediatorCancer Research Communications · 2024
  50. Tumor intrinsic activity of Chromobox 2 (CBX2) remodels the tumor microenvironment in high grade serous carcinomaCancer Research Communications · 2024